OraSure Technologies (NASDAQ:OSUR - Get Free Report) was downgraded by research analysts at StockNews.com from a "buy" rating to a "hold" rating in a research note issued on Tuesday.
OraSure Technologies Trading Up 4.4 %
Shares of OSUR stock traded up $0.15 on Tuesday, reaching $3.46. 402,808 shares of the company's stock were exchanged, compared to its average volume of 934,887. The company's fifty day simple moving average is $3.75 and its 200 day simple moving average is $3.98. OraSure Technologies has a 52 week low of $2.68 and a 52 week high of $7.43. The stock has a market capitalization of $257.72 million, a PE ratio of 23.10 and a beta of -0.02.
Insider Transactions at OraSure Technologies
In other news, CEO Manner Carrie Eglinton bought 78,625 shares of the firm's stock in a transaction that occurred on Thursday, February 27th. The stock was purchased at an average cost of $3.15 per share, for a total transaction of $247,668.75. Following the purchase, the chief executive officer now directly owns 1,259,664 shares in the company, valued at approximately $3,967,941.60. This trade represents a 6.66 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director John P. Kenny bought 47,659 shares of the company's stock in a transaction dated Thursday, February 27th. The shares were acquired at an average price of $3.17 per share, for a total transaction of $151,079.03. Following the completion of the transaction, the director now directly owns 70,915 shares in the company, valued at approximately $224,800.55. This trade represents a 204.93 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders bought a total of 190,284 shares of company stock worth $600,348 over the last three months. 3.40% of the stock is currently owned by insiders.
Institutional Investors Weigh In On OraSure Technologies
Large investors have recently bought and sold shares of the company. BNP Paribas Financial Markets increased its stake in shares of OraSure Technologies by 27.2% in the 3rd quarter. BNP Paribas Financial Markets now owns 855,951 shares of the medical instruments supplier's stock worth $3,655,000 after acquiring an additional 183,191 shares during the last quarter. Franklin Resources Inc. raised its stake in shares of OraSure Technologies by 28.5% in the 3rd quarter. Franklin Resources Inc. now owns 269,269 shares of the medical instruments supplier's stock valued at $1,091,000 after acquiring an additional 59,723 shares during the period. JPMorgan Chase & Co. lifted its holdings in shares of OraSure Technologies by 5.8% in the 3rd quarter. JPMorgan Chase & Co. now owns 847,933 shares of the medical instruments supplier's stock worth $3,621,000 after acquiring an additional 46,216 shares during the last quarter. Barclays PLC lifted its stake in OraSure Technologies by 182.6% during the 3rd quarter. Barclays PLC now owns 195,793 shares of the medical instruments supplier's stock worth $836,000 after acquiring an additional 126,503 shares in the last quarter. Finally, Exchange Traded Concepts LLC purchased a new position in shares of OraSure Technologies in the fourth quarter valued at approximately $287,000. 93.50% of the stock is currently owned by hedge funds and other institutional investors.
OraSure Technologies Company Profile
(
Get Free Report)
OraSure Technologies, Inc, together with its subsidiaries, provides point-of-care and home diagnostic tests, specimen collection devices, and microbiome laboratory and analytical services in the United States, Europe, and internationally. The company's products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D.
Featured Stories
Before you consider OraSure Technologies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and OraSure Technologies wasn't on the list.
While OraSure Technologies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Get this report to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
